Category Archives: Other

Novo Initiates Ph1 Oral ASCL5 Inhibitor Study for Obesity; FDA to Host Public Feedback Meeting on CNPV; March CHMP Agenda

Three cardiometabolic-related news items have been observed: Lexicon Pharmaceuticals and Novo Nordisk initiated a Ph1 obesity study of its oral ASCL5 inhibitor (view press release); FDA shared plans to host a public feedback meeting regarding the CNPV pilot program (view press release); and the CHMP agenda for this month’s meeting (March 23-26) has been released (view agenda). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Novo Initiates Ph3 Zenagamtide Obesity and Knee OA Study; Biohaven Completes Enrollment in its Ph2b Obesity Study

Two cardiometabolic-related news items have been observed: Novo Nordisk has initiated its Ph3 AMAZE 5 study of zenagamtide in knee OA (view CT.gov record); and Biohaven announced it completed enrollment for its Ph2b POC study evaluating QW and QM formulations of taldefgrobep alfa (view press release). Below, FENIX provides highlights and insights on the respective news items, including thoughts on Novo’s decision not to conduct AMAZE 5 H2H vs. tirzepatide.

This content is for Read Less members only.
Already a member? Log in here

MiniMed Flex Receives FDA Clearance; MetaVia Advances DA-1726 in Obesity; Ascletis Selects Another Obesity Candidate

Three cardiometabolic-related news items have been observed: MiniMed Flex received FDA clearance and launched its MiniMed Forward Program (view press release); MetaVia received IRB approval to advance DA-1726 in obesity (view press release); and Ascletis Pharma selected its oral amylin ASC39 as its next obesity candidate (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

ATTD 2026 Key Press Releases (March 13)

On the third day of ATTD 2026, four cardiometabolic-related news items have been observed from Insulet, TIXiMED, Biocon, and Sana Biotechnology. Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.
Already a member? Log in here

ATTD 2026 Key Press Releases (March 12)

On the second day of ATTD 2026, three cardiometabolic-related news items have been observed: Lilly issued a public warning letter regarding the risk of compounded tirzepatide (view press release); Breakthrough T1D released a statement on cadaver donor islet cells and the ISLET Act (view press release); and Abbott shared results from its FreeDM2 study comparing Libre vs. SMBG in T2DM basal patients (view press release). Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.
Already a member? Log in here

ATTD 2026 Key Press Releases (March 11)

On the first day of ATTD 2026, four cardiometabolic-related news items have been observed from Skye Bioscience, Lilly, MiniMed, and LifeScan. Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Kailera Initiates Another Ph2 Ribupatide Study; Ascletis Reports Topline Ph2 Data; Laekna Announces Topline Ph1 Data; Glooko Connects with Roche’s CGM; SK pharmteco to Manufacture Long-Acting API for Current Lilly Product; Novo Acknowledges FDA Form 483

A series of cardiometabolic-related news items has been observed from Kailera, Ascletis Pharma, Laekna, Glooko, SK pharmteco, and Novo Nordisk. Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Novo and Hims Take Another Turn at a Partnership; AbbVie Reports Topline Ph1 Amylin Data; Regeneron & Hansoh Share Ph3 Olatorepatide China Results; Lilly Releases Statement on CMS Obesity BALANCE Model; Zepbound KwikPen Available on Amazon; Veru Enrolls First Patient in Ph2b PLATEAU Study; Sequel Expands AID Launch 

A series of cardiometabolic-related news items has been observed from Novo Nordisk/Hims & Hers, AbbVie, Regeneron Pharmaceuticals/Hansoh, Lilly, Amazon, Veru, and Sequel Med Tech. Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Thoughts on Ph2 ZUPREME-1 Data: Can Petrelintide Still Compete?

Recently, Zealand announced topline 42-week results from the Ph2 ZUPREME-1 study, which evaluated petrelintide (QW SC amylin analog) in adults with obesity or overweight (previous FENIX insight). Following the announcement, Zealand’s share price declined -36%, reflecting investor disappointment in petrelintide’s weight loss efficacy (up to -10.7%), despite an otherwise favorable tolerability profile. Below, FENIX provides a thoughts-on analysis of the topline ZUPREME-1 data, including a deep-dive on how petrelintide’s benefit/risk profile compares to other amylin analogs in development, as well as why amylin may fall short of Zealand’s expectations for it becoming the next foundational AOM.

This content is for Read Less members only.
Already a member? Log in here